As per a Sanofi statement, Opella has a presence in over 100 countries and has a workforce of over 11,000 employees. The division possesses 13 production plants and 4 research and innovation centers.
The Financial Times reported that CD&R outbid competitors for Sanofi's division Opella, valuing it at 15.5 billion euros, according to sources.
Sanofi stated that they have not yet reached an agreement, additional information about the possible sale of a stake in Opella will be disclosed once a decision is reached.
Opella produces non-prescription medications, vitamin and mineral blends, and dietary supplements. It contains over 100 brands in its collection, such as Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax.
Opella currently functions as a separate entity under Sanofi, as stated in the press release.
source: ft.com
The Financial Times reported that CD&R outbid competitors for Sanofi's division Opella, valuing it at 15.5 billion euros, according to sources.
Sanofi stated that they have not yet reached an agreement, additional information about the possible sale of a stake in Opella will be disclosed once a decision is reached.
Opella produces non-prescription medications, vitamin and mineral blends, and dietary supplements. It contains over 100 brands in its collection, such as Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax.
Opella currently functions as a separate entity under Sanofi, as stated in the press release.
source: ft.com